Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.
Choose from the criteria below to find an activity that fits you best.
Note: If you attended the live CE activity AND received CE credit (i.e. a pharmacist CE statement of credit with ACPE UAN 0221-0000-17-425-L07-P, or a nurse CE certificate), you are NOT allowed to also receive credit for this home-study on-demand web activity.
The United States Pharmacopeial Convention (USP) recently established new standards
for handling designated hazardous drugs: General Chapter <800> Hazardous Drugs—Handling
in Healthcare Settings. USP encourages adoption and implementation of these standards
to help ensure a quality environment and protection of healthcare workers and patients
when hazardous drugs are handled.
Health-system pharmacy departments will need to invest significant time and resources to achieve full compliance. Yet, a recent survey showed that only 5% of hospital pharmacy departments currently meet or exceed the new USP <800> requirements. These include:
Pharmacists and nurses who participate in this activity will be presented with a review of the USP <800> requirements and timelines, as well as the test protocol developed by the National Institute for Occupational Safety and Health (NIOSH) for closed system transfer devices (CSTDs). The discussion will cover facility and engineering controls (e.g., CSTDs, personal protective equipment, and waste management), self-assessment tools for compliance, solutions for noncompliant areas, and considerations for interprofessional collaboration between pharmacists and nurses.
The target audience for this activity includes pharmacists and nurses in health-system settings. After completing the activity, participants should be able to:
Fred Massoomi, PharmD, FASHP
Senior Director of Health-system & Hospital Services
Thomas H. Connor, PhD
Centers for Disease Control and Prevention
National Institute for Occupational Safety and Health
Seth Eisenberg RN, ASN, OCN®, BMTCN™
Professional Practice Coordinator
Seattle Cancer Care Alliance
Release Date: 1-16-2018
Expiration Date: 1-16-2019
ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-18-013-H07-P has been assigned to this home-study knowledge-based activity (initial release date 1-16-18). This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. Statements of completion will be issued online at www.ProCE.com and proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
This CE activity is jointly provided by ProCE, Inc. and Wild Iris Medical Education,
Inc. This activity provides 1.5 contact hours of nurse CE credit.
Wild Iris Medical Education, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and
scientific rigor in all of its continuing education activities. Faculty must disclose
to participants any significant financial interest or affiliation with companies that
manufacture or market products discussed during their presentation. Dr. Connor has
no relevant commercial or financial relationships to disclose. Mr. Eisenberg is a
Speaker for B Braun, BD, ICU Medical, and Medtronic. Dr. Massoomi is an employee of
Visante, Inc. and is a Speaker for ICU Medical. A portion of grant funds received
by ProCE from ICU Medical will be used to compensate the faculty for this presentation.
Please note: The opinions expressed in this activity should not be construed as those of the CE provider. The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.
This activity is provided by ProCE, Inc. and is supported by an educational grant from ICU Medical.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.